Table 1.
Clinical Characteristics of Patients Receiving Intermittent Liposomal Amphotericin B Prophylaxis
| Characteristic | Patients, n = 198 (%) |
|---|---|
| Male sex, no. (%) | 123 (62) |
| Age at diagnosis, mean (range) | 52 (16–83) |
| Weight, mean (range, kg) | 74 (31–165) |
| Ethnic origin, no. (%) | |
| Caucasian | 166 (84) |
| Asian | 12 (6.1) |
| Indian subcontinent | 7 (3.5) |
| Pacific Islander | 3 (1.5) |
| Middle Eastern | 6 (3.0) |
| African | 3 (1.5) |
| Hispanic | 1 (0.5) |
| Comorbidities, no. (%) | |
| Diabetes | 34 (17) |
| Chronic kidney disease | 12 (6.1) |
| Chronic liver disease | 13 (6.6) |
| Underlying hematological disease, no. (%) | |
| Acute myeloid leukemia | 92 (46) |
| Acute lymphoblastic leukemia | 53 (27) |
| Acute promyelocytic leukemia | 16 (8.1) |
| Non-Hodgkin’s lymphoma | 13 (6.6) |
| Multiple myeloma | 10 (5.1) |
| Chronic myeloid leukemia | 4 (2.0) |
| Chronic lymphocytic leukemia | 1 (0.5) |
| Myelodysplastic syndrome | 4 (2.0) |
| Hodgkin’s lymphoma | 2 (1.0) |
| Myelofibrosis | 2 (1.0) |
| Blastic plasmacytoid dendritic cell neoplasm | 1 (0.5) |
| HSCT recipients | 29 (15) |
| HSCT type, no. (%) | |
| Allogeneic | 27 (93) |
| Autologous | 2 (6.9) |
| Allograft characteristics, n = 27 | |
| HLA matched | 13 (48) |
| Single antigen mismatch | 1 (3.7) |
| Unrelated donor | 13 (48) |
| Presence of GVHD | 21 (78) |
| Clinical outcomes | |
| ICU admission | 57 (29) |
| 30-day mortality from last dose, n = 196a | 33 (17) |
| 12-week mortality from last dose, n = 193a | 42 (22) |
Abbreviations: GVHD, graft versus host disease; HLA, human leucocyte antigen; HSCT, hematopoietic stem cell transplant; ICU, intensive care unit.
aTwo and 5 patients were lost to follow-up before 30 days and 12 weeks, respectively.